Invokana belongs to a relatively new class of type 2 diabetes drugs called SGLT-2 inhibitors, which helps remove excess blood sugar through urine. The FDA just recently required Invokana to include a warning about a high risk of foot and leg amputations in diabetic patients. This change in the required warning is the result of two clinical trials that concluded that leg and foot amputations occurred about twice as often in patients with type 2 diabetes treated with Invokana, which puts a great many diabetic patients using Invokana at risk.
Without this enhanced warning, which is essential product information, patients have not been able to make a fully informed, intelligent decision about whether to use the drug with its attendant risks.
If you or a loved one have suffered an amputation while using Invokana, or an injury caused by any other prescription drug, please contact Leeseberg Tuttle for more information.